EUVIMEDEUVIMED entdecken
Open Access

Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma

Jianming He iD, Karen Chiang iD, Xiwu Lin, Winghan Jacqueline Kwong, John Maringwa iD, Lingfeng Yang iD, Sandhya Nair, Mahmoud Hashim, Mi Jun Keng iD, Imtiaz A Samjoo iD

Journal of Comparative Effectiveness Research · 2025-10 · 14 (10)

DOI: 10.57264/cer-2024-0180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025-10. Verfasst von Jianming He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Johnson and Johnson, Raritan, NJ 08869, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We aimed to identify variables that affect the prognosis and treatment effect in multiple myeloma (MM). Materials & methods: Published literature of randomized controlled trials (RCTs) and population-adjusted indirect comparisons (PAICs) in newly diagnosed (ND) and relapsed/refractory (RR) MM populations reporting overall survival (OS) and progression-free survival (PFS) were identified. Possible treatment effect modifiers (TEMs) were evaluated based on the ratio between effect estimates of different strata within subgroups for OS and PFS among eligible RCTs. Potential prognostic factors (PFs) were identified using the lists of covariates adjusted for in PAICs meeting the eligibility criteria.

Results

Sixty-five RCTs and 59 PAICs were included for synthesis. In ND-MM and RR-MM patients, age, sex, International Staging System stage, and cytogenetics were identified as potential TEMs for PFS based on data from published RCTs. Refractory disease, prior therapy exposure status and creatinine clearance were additional TEMs for PFS in RR-MM patients. Eastern Cooperative Oncology Group performance score and creatinine clearance were TEM candidates of PFS for ND-MM stem-cell transplant-ineligible patients. No consistent TEMs for OS were identified across all MM populations. Commonly adjusted variables for both OS and PFS in published PAICs of all populations aligned with potential TEMs of PFS identified in published RCTs. Additionally, subtype of MM, time since diagnosis and extramedullary disease or presence of plasmacytoma were common variables for adjustment in PAICs evaluating RR-MM. Frequency of each variable adjusted for differs by population and outcome. Only one PAIC reported TEMs separately from PFs.

Conclusion

TEMs and PFs identified herein can help inform future clinical trial design and serve as a primer when conducting PAICs evaluating OS and PFS in ND/RR-MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansPrognosisRandomized Controlled Trials as TopicProgression-Free SurvivalNeoplasm Recurrence, LocalMale

Stichwörter der Autor:innen

literature reviewmultiple myelomapopulation-adjusted indirect comparisonsprognostic factorstreatment effect modifiers

Autor:innen und Institutionen

  • Johnson and Johnson, Raritan, NJ 08869, USA.
  • EVERSANA™, ON L7N 3H8, Canada.
  • Clinical Pharmacology and Pharmacometrics, Johnson and Johnson, Breda, Netherlands.
  • Johnson and Johnson, Beerse, Belgium.

ORCID-Profile: Jianming He, Karen Chiang, John Maringwa, Lingfeng Yang, Mi Jun Keng, Imtiaz A Samjoo

Zitieren

APA

He, J., Chiang, K., Lin, X., Kwong, W. J., Maringwa, J., Yang, L., Nair, S., Hashim, M., Keng, M. J., & Samjoo, I. A. (2025). Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma. Journal of Comparative Effectiveness Research, 14(10). https://doi.org/10.57264/cer-2024-0180

Vancouver

He J, Chiang K, Lin X, Kwong WJ, Maringwa J, Yang L, et al. Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma. Journal of Comparative Effectiveness Research. 2025;14(10). doi:10.57264/cer-2024-0180

BibTeX
@article{He2025,
  author = {He, Jianming and Chiang, Karen and Lin, Xiwu and Kwong, Winghan Jacqueline and Maringwa, John and Yang, Lingfeng and Nair, Sandhya and Hashim, Mahmoud and Keng, Mi Jun and Samjoo, Imtiaz A},
  title = {Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  volume = {14},
  number = {10},
  doi = {10.57264/cer-2024-0180}
}
Kostenlos starten →